

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-44 (canceled)

Claim 45 (new) An olanzapine salt comprising olanzapine fumarate.

Claim 46 (new) The olanzapine salt of claim 45, wherein the salt is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein said X-ray diffraction pattern comprises peaks selected from the group consisting of:

- (i) 9.49, 13.99, and 15.83 degrees;
- (ii) 12.71, 17.13, and 19.67 degrees;
- (iii) 21.43, 22.29, and 22.99 degrees;
- (iv) 9.49 degrees;
- (v) 9.49 and 13.99 degrees; and
- (vi) 15.83 and 22.29 degrees.

Claim 47 (new) The olanzapine salt of claim 45, wherein said salt is crystalline.

Claim 48 (new) The olanzapine salt of claim 45, wherein said salt exhibits a powder X-ray diffraction pattern substantially as shown in Figure 1.

Claim 49 (new) A pharmaceutical composition comprising the olanzapine salt of claim 45.

Claim 50 (new) An olanzapine salt comprising olanzapine maleate.

Claim 51 (new) The olanzapine salt of claim 50, wherein the salt is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein said X-ray diffraction pattern comprises peaks selected from the group consisting of:

- (i) 5.57, 12.95, and 16.79 degrees;
- (ii) 11.97, 19.25, and 21.11 degrees;
- (iii) 5.57, 19.25, and 22.23 degrees;
- (iv) 5.57 degrees;
- (v) 5.57 and 12.95 degrees; and
- (vi) 16.79 and 19.25 degrees.

Claim 52 (new) The olanzapine salt of claim 50, wherein said salt is crystalline.

Claim 53 (new) The olanzapine salt of claim 50, wherein said salt exhibits a powder X-ray diffraction pattern substantially as shown in Figure 3.

Claim 54 (new) A pharmaceutical composition comprising the olanzapine salt of claim 50.

Claim 55 (new) An olanzapine salt comprising olanzapine malonate.

Claim 56 (new) The olanzapine salt of claim 55, wherein the salt is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein said X-ray diffraction pattern comprises peaks selected from the group consisting of:

- (i) 7.37, 9.45, and 12.41 degrees;
- (ii) 14.83, 20.51, and 21.35 degrees;
- (iii) 7.37, 17.71, and 23.19 degrees;
- (iv) 7.37 degrees;
- (v) 9.45 and 12.95 degrees; and
- (vi) 9.85 and 17.71 degrees.

Claim 57 (new) The olanzapine salt of claim 55, wherein said salt is crystalline.

Claim 58 (new) The olanzapine salt of claim 55, wherein said salt exhibits a powder X-ray diffraction pattern substantially as shown in Figure 5.

Claim 59 (new). A pharmaceutical composition comprising the olanzapine salt of claim 55.

Claim 60 (new) An olanzapine solvate comprising methanol.

Claim 61 (new) The olanzapine solvate of claim 60, wherein the solvate is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein said X-ray diffraction pattern comprises peaks selected from the group consisting of:

- (i) 8.61, 16.45, and 18.85 degrees;
- (ii) 16.45, 19.97, and 23.09 degrees;
- (iii) 20.85, 22.05, and 24.73 degrees;
- (iv) 8.61 degrees;
- (v) 8.61 and 16.45 degrees; and
- (vi) 18.85 and 19.97 degrees.

Claim 62 (new) The olanzapine solvate of claim 60, wherein the solvate exhibits a single-crystal x-ray analysis with crystal parameters that are approximately equal to the following:  $a = 10.1416(8)$  angstroms,  $b = 12.2793(9)$  angstroms,  $c = 14.1147(11)$  angstroms,  $\beta = 91.7860(10)$  degrees.

Claim 63 (new) The olanzapine solvate of claim 60, wherein said solvate is crystalline.

Claim 64 (new) The olanzapine solvate of claim 60, wherein said solvate exhibits a powder X-ray diffraction pattern substantially as shown in Figure 6.

Claim 65 (new) A pharmaceutical composition comprising the olanzapine solvate of claim 60.

Claim 66 (new) An olanzapine co-crystal comprising olanzapine and nicotinamide.

Claim 67 (new) The olanzapine co-crystal of claim 66, wherein said co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein said X-ray diffraction pattern comprises peaks selected from the group consisting of:

- (i) 4.89, 8.65, and 17.17 degrees;
- (ii) 23.97, 24.61, and 25.57 degrees;
- (iii) 4.89, 17.17, and 25.57 degrees;
- (iv) 4.89 degrees;
- (v) 4.89 and 8.65 degrees; and
- (vi) 17.17 and 23.97 degrees.

Claim 68 (new) The olanzapine co-crystal of claim 66, wherein said co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein said X-ray diffraction pattern comprises peaks selected from the group consisting of:

- (i) 8.65, 11.87, and 14.53 degrees;
- (ii) 17.53, 18.09, and 23.89 degrees;
- (iii) 8.65, 17.53, and 24.19 degrees;
- (iv) 8.65 degrees;
- (v) 11.87 and 14.53 degrees; and
- (vi) 18.09 and 23.89 degrees.

Claim 69 (new) The olanzapine co-crystal of claim 66, wherein said co-crystal is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein said X-ray diffraction pattern comprises peaks selected from the group consisting of:

- (i) 6.43, 12.85, and 18.69 degrees;
- (ii) 9.55, 14.91, and 21.85 degrees;
- (iii) 6.43, 14.91, and 19.83 degrees;
- (iv) 6.43 degrees;
- (v) 12.85 and 18.69 degrees; and
- (vi) 6.43 and 21.85 degrees.

Claim 70 (new) The olanzapine co-crystal of claim 66, wherein said co-crystal exhibits a single-crystal x-ray analysis with crystal parameters that are approximately equal to the following:  $a = 14.0961(12)$  angstroms,  $b = 12.5984(10)$  angstroms,  $c = 27.219(2)$  angstroms,  $\beta = 97.396(2)$  degrees.

Claim 71 (new) The olanzapine co-crystal of claim 66, wherein said co-crystal exhibits a powder X-ray diffraction pattern substantially as shown in a figure selected from the group consisting of Figure 14B, Figure 16, and Figure 17B.

Claim 72 (new) A pharmaceutical composition comprising the olanzapine co-crystal of claim 66.

Claim 73 (new) An olanzapine solvate comprising propylene glycol.

Claim 74 (new) The olanzapine solvate of claim 73, wherein said solvate is characterized by a powder X-ray diffraction pattern comprising peaks expressed in terms of 2-theta angles, wherein said X-ray diffraction pattern comprises peaks selected from the group consisting of :

- (i) 8.39, 11.71, and 15.55 degrees;
- (ii) 13.95, 15.55, and 19.55 degrees;
- (iii) 14.45, 17.91, and 21.47 degrees;
- (iv) 8.39 degrees;
- (v) 8.39 and 21.47 degrees; and
- (vi) 11.71 and 15.55 degrees.

Claim 75 (new) The olanzapine solvate of claim 73, wherein said solvate exhibits a single-crystal x-ray analysis with crystal parameters that are approximately equal to the following:  $a = 10.4264(9)$  angstroms,  $b = 13.3916(11)$  angstroms,  $c = 14.4424(12)$  angstroms,  $\beta = 95.503(2)$  degrees.

Claim 76 (new) The olanzapine solvate of claim 73, wherein said solvate is crystalline.

Claim 77 (new) The olanzapine solvate of claim 73, wherein said solvate exhibits a powder X-ray diffraction pattern substantially as shown in Figure 10B.

Claim 78 (new) A pharmaceutical composition comprising the olanzapine solvate of claim 73.

Claim 79 (new) A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition of claim 49 to a patient suffering from psychosis, a functional bowel disorder, or irritable bowel syndrome.

Claim 80 (new) A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition of claim 54 to a patient suffering from psychosis, a functional bowel disorder, or irritable bowel syndrome.

Claim 81 (new) A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition of claim 59 to a patient suffering from psychosis, a functional bowel disorder, or irritable bowel syndrome.

Claim 82 (new) A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition of claim 65 to a patient suffering from psychosis, a functional bowel disorder, or irritable bowel syndrome.

Claim 83 (new) A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition of claim 72 to a patient suffering from psychosis, a functional bowel disorder, or irritable bowel syndrome.

Claim 84 (new) A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition of claim 78 to a patient suffering from psychosis, a functional bowel disorder, or irritable bowel syndrome.